Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Erik P. Sulman, Minhee Won, Deborah T. Blumenthal, Michael A. Vogelbaum, Howard Colman, Robert B. Jenkins, Arnab Chakravarti, Robert Jeraj, Paul D. Brown, Kurt A. Jaeckle, David Schiff, James Dignam, James Norman Atkins, David Brachman, Maria Werner-Wasik, Ritsuko Komaki, Mark R. Gilbert, Minesh P. Mehta, Kenneth D. Aldape
Institutions: The University of Texas MD Anderson Cancer Center, RTOG Foundation, Tel Aviv Sourasky Medical Center, Cleveland Clinic, University of Utah, Huntsman Cancer Institute, Mayo Clinic, The Ohio State University, University of Wisconsin–Madison, Mayo Clinic in Florida, University of Virginia Medical Center, NSABP Foundation, Thomas Jefferson University Hospital, University of Maryland, Baltimore
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4242380496